CR63 Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?
Džana Bjelić, Sara Bognar, Jelena Benčić, Manuela Bajan, Natalija Dedić Plavetić

School of Medicine, University of Zagreb, Zagreb, Croatia
Division of Medical Oncology, Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia

DOI: https://doi.org/10.26800/LV-145-suapl2-CR63

CR64 Posaconazole-induced Glucocorticoid Deficiency in a Patient with Myelodysplastic syndrome.
Antonia Precali, Ivana Kraljević

School of Medicine, University of Zagreb, Zagreb, Croatia
Department of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia

DOI: https://doi.org/10.26800/LV-145-suapl2-CR64

KEYWORDS: breast cancer; metastasis; pneumonitis; trastuzumab deruxtecan

INTRODUCTION/OBJECTIVES: Breast cancer overexpressing the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2-directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal antibody trastuzumab with the topoisomerase I inhibitor deruxtecan. It exhibits significant anti-tumor activity in previously overtreated patients.

CASE PRESENTATION: In January 2023, a 59-year-old woman with a history of HER2-positive metastatic breast cancer presented to the emergency room (ER) with shallow, fast breathing, dry cough, chest tightness, and intolerance to physical activity that had persisted for two days prior to admission. Additionally, she had a fever of up to 38.5 °C a week before, which was managed with acetaminophen. In 2016, she was diagnosed with early breast cancer and underwent a left mastectomy, adjuvant chemotherapy and anti-HER2 monoclonal antibody trastuzumab. Unfortunately, the patient developed lung metastases in 2017. Since then, she has taken antibiotics and antifungal prophylaxis, including posaconazole. Diagnosis of primary glucocorticoid insufficiency was made, most likely due to the intake of posaconazole. Normal potassium and sodium levels with normal aldosterone and renin levels and normal blood pressure suggested intact mineralocorticoid adrenal function. Substitution therapy with hydrocortisone was initiated, and subsequent check-ups showed normal findings with improved symptoms.

CONCLUSION: Posaconazole is an azole medication that is used in the treatment and prophylaxis of many fungal infections. However, some studies show that antifungals such as ketoconazole and posaconazole disrupt the steroid biosynthesis pathway and possibly can lead to adrenal disorders. The presented case shows a correlation between posaconazole usage and glucocorticoid deficiency, emphasizing the need to carefully monitor patients on posaconazole therapy.